Lupus therapy.
Baart de la Faille
H
H
University Hospital Utrecht, Department of Dermatology and Venereology, The Netherlands.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D017373:Cyproterone Acetate / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008297:Male; D010956:Plasmapheresis; D011994:Recombinant Proteins; D013473:Sunscreening Agents
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D000962:Antimalarials; D004965:Estrogen Antagonists; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013473:Sunscreening Agents; D017373:Cyproterone Acetate; D003520:Cyclophosphamide